NASDAQ:MDWD - Mediwound Stock Price, Forecast & News

Mediwound trades on the NASDAQ under the ticker symbol "MDWD."

Mediwound Ltd (NASDAQ:MDWD) announced its earnings results on Thursday, November, 14th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.12. The biopharmaceutical company had revenue of $5.14 million for the quarter, compared to the consensus estimate of $2.67 million. Mediwound had a net margin of 69.50% and a negative return on equity of 94.57%. View Mediwound's Earnings History.

Mediwound is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Mediwound.

2 brokers have issued 1-year target prices for Mediwound's stock. Their forecasts range from $5.50 to $7.00. On average, they anticipate Mediwound's share price to reach $6.25 in the next year. This suggests a possible upside of 106.3% from the stock's current price. View Analyst Price Targets for Mediwound.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mediwound.

News headlines about MDWD stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mediwound earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Mediwound.

Some companies that are related to Mediwound include Sundial Growers (SNDL), Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), True Drinks (TRUU), Tauriga Sciences (TAUG), GLG Life Tech (GLGLF), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Beleave (BE) and Beleave (BE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mediwound investors own include Opko Health (OPK), Blackstone Group (BX), Mastercard (MA), Wells Fargo & Co (WFC), Caesarstone (CSTE), Chubb (CB), Nordic American Tanker (NAT), Braskem (BRKMY), Novavax (NVAX) and Inovio Pharmaceuticals (INO).

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MDWD stock can currently be purchased for approximately $3.03.

Mediwound has a market capitalization of $82.35 million and generates $3.40 million in revenue each year. The biopharmaceutical company earns $-1,060,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Mediwound employs 73 workers across the globe.View Additional Information About Mediwound.

The official website for Mediwound is http://www.mediwound.com/.

Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]